Startseite>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>Valecobulin (CKD-516)

Valecobulin (CKD-516) (Synonyms: CKD-516)

Katalog-Nr.GC33269

Valecobulin (CKD-516) (CKD516) ist ein Valin-Prodrug von (S516) und ein vaskulÄr aufbrechendes Mittel (VDA). Valecobulin (CKD-516) ist ein potenter β-Tubulin-Polymerisationsinhibitor mit ausgeprÄgter AntitumoraktivitÄt gegen murine und humane solide Tumore.

Products are for research use only. Not for human use. We do not sell to patients.

Valecobulin (CKD-516) Chemische Struktur

Cas No.: 1188371-47-2

Größe Preis Lagerbestand Menge
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Valecobulin (CKD516), a valine prodrug of (S516) and a vascular disrupting agent (VDA), is a potent beta-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2].

The size change of the tumor in VX2 liver tumor-bearing rabbits is significantly smaller in the Valecobulin (CKD516)( 5, 9, or 12 mg/m2, i.v.)- treated group than in control group[2].|| Animal Model:|VX2 liver tumor-bearing rabbits (Male New Zealand White rabbits weighing between 2.5 and 3.5 kg)[2]. |Dosage:|Dissolved in 5 mL of saline at a dose of 5, 9, or 12 mg/m2 of body surface area.|Administration:|Intravenous injection once.|Result:|The size change of the tumors was significantly smaller in the treated group than in control group.

[1]. Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. [2]. Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272(2):417-26.

Bewertungen

Review for Valecobulin (CKD-516)

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Valecobulin (CKD-516)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.